Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID23866879.
Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.”. Journal of the American Academy of Dermatology69 (2): 173.e1-13; quiz 185–6. doi:10.1016/j.jaad.2013.05.003. PMID23866878.
Bastuji-Garin, S; Rzany, B; Stern, RS; Shear, NH; Naldi, L; Roujeau, JC (January 1993). “Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.”. Archives of dermatology129 (1): 92–6. doi:10.1001/archderm.129.1.92. PMID8420497.
Jordan, MH; Lewis, MS; Jeng, JG; Rees, JM (1991). “Treatment of toxic epidermal necrolysis by burn units: another market or another threat?”. The Journal of burn care & rehabilitation12 (6): 579–81. doi:10.1097/00004630-199111000-00015. PMID1779014.
Roujeau, JC; Stern, RS (10 November 1994). “Severe adverse cutaneous reactions to drugs.”. The New England Journal of Medicine331 (19): 1272–85. doi:10.1056/nejm199411103311906. PMID7794310.
Morales, ME; Purdue, GF; Verity, SM; Arnoldo, BD; Blomquist, PH (October 2010). “Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.”. American journal of ophthalmology150 (4): 505–510.e1. doi:10.1016/j.ajo.2010.04.026. PMID20619392.
Hung, SI; Chung, WH; Jee, SH; Chen, WC; Chang, YT; Lee, WR; Hu, SL; Wu, MT et al. (April 2006). “Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.”. Pharmacogenetics and genomics16 (4): 297–306. doi:10.1097/01.fpc.0000199500.46842.4a. PMID16538176.
McCormack, M; Alfirevic, A; Bourgeois, S; Farrell, JJ; Kasperavičiūtė, D; Carrington, M; Sills, GJ; Marson, T et al. (24 March 2011). “HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.”. The New England Journal of Medicine364 (12): 1134–43. doi:10.1056/nejmoa1013297. PMID21428769.
Tohkin, M; Kaniwa, N; Saito, Y; Sugiyama, E; Kurose, K; Nishikawa, J; Hasegawa, R; Aihara, M et al. (February 2013). “A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.”. The pharmacogenomics journal13 (1): 60–9. doi:10.1038/tpj.2011.41. PMID21912425.
Schwartz, RA; McDonough, PH; Lee, BW (Aug 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID23866879.
Zajicek, R; Pintar, D; Broz, L; Suca, H; Königova, R (May 2012). “Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008.”. Journal of the European Academy of Dermatology and Venereology : JEADV26 (5): 639–43. doi:10.1111/j.1468-3083.2011.04143.x. PMID21668825.
Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID23866879.
DeMers, G; Meurer, WJ; Shih, R; Rosenbaum, S; Vilke, GM (December 2012). “Tissue plasminogen activator and stroke: review of the literature for the clinician.”. The Journal of emergency medicine43 (6): 1149–54. doi:10.1016/j.jemermed.2012.05.005. PMID22818644.
Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID23866879.
Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.”. Journal of the American Academy of Dermatology69 (2): 173.e1-13; quiz 185–6. doi:10.1016/j.jaad.2013.05.003. PMID23866878.
Bastuji-Garin, S; Rzany, B; Stern, RS; Shear, NH; Naldi, L; Roujeau, JC (January 1993). “Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.”. Archives of dermatology129 (1): 92–6. doi:10.1001/archderm.129.1.92. PMID8420497.
Jordan, MH; Lewis, MS; Jeng, JG; Rees, JM (1991). “Treatment of toxic epidermal necrolysis by burn units: another market or another threat?”. The Journal of burn care & rehabilitation12 (6): 579–81. doi:10.1097/00004630-199111000-00015. PMID1779014.
Roujeau, JC; Stern, RS (10 November 1994). “Severe adverse cutaneous reactions to drugs.”. The New England Journal of Medicine331 (19): 1272–85. doi:10.1056/nejm199411103311906. PMID7794310.
Morales, ME; Purdue, GF; Verity, SM; Arnoldo, BD; Blomquist, PH (October 2010). “Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.”. American journal of ophthalmology150 (4): 505–510.e1. doi:10.1016/j.ajo.2010.04.026. PMID20619392.
Hung, SI; Chung, WH; Jee, SH; Chen, WC; Chang, YT; Lee, WR; Hu, SL; Wu, MT et al. (April 2006). “Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.”. Pharmacogenetics and genomics16 (4): 297–306. doi:10.1097/01.fpc.0000199500.46842.4a. PMID16538176.
McCormack, M; Alfirevic, A; Bourgeois, S; Farrell, JJ; Kasperavičiūtė, D; Carrington, M; Sills, GJ; Marson, T et al. (24 March 2011). “HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.”. The New England Journal of Medicine364 (12): 1134–43. doi:10.1056/nejmoa1013297. PMID21428769.
Tohkin, M; Kaniwa, N; Saito, Y; Sugiyama, E; Kurose, K; Nishikawa, J; Hasegawa, R; Aihara, M et al. (February 2013). “A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.”. The pharmacogenomics journal13 (1): 60–9. doi:10.1038/tpj.2011.41. PMID21912425.
Schwartz, RA; McDonough, PH; Lee, BW (Aug 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID23866879.
Zajicek, R; Pintar, D; Broz, L; Suca, H; Königova, R (May 2012). “Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008.”. Journal of the European Academy of Dermatology and Venereology : JEADV26 (5): 639–43. doi:10.1111/j.1468-3083.2011.04143.x. PMID21668825.
Schwartz, RA; McDonough, PH; Lee, BW (August 2013). “Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.”. Journal of the American Academy of Dermatology69 (2): 187.e1-16; quiz 203–4. doi:10.1016/j.jaad.2013.05.002. PMID23866879.
DeMers, G; Meurer, WJ; Shih, R; Rosenbaum, S; Vilke, GM (December 2012). “Tissue plasminogen activator and stroke: review of the literature for the clinician.”. The Journal of emergency medicine43 (6): 1149–54. doi:10.1016/j.jemermed.2012.05.005. PMID22818644.